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Abstract
Background: The BRCA2-8765delAG mutation was firstly described in breast cancer families from
French-Canadian and Jewish-Yemenite populations; it was then reported as a founder mutation in
Sardinian families. We evaluated both the prevalence of the BRCA2-8765delAG variant in Sardinia
and the putative existence of a common ancestral origin through a haplotype analysis of breast
cancer family members carrying such a mutation.
Methods:  Eight polymorphic microsatellite markers (D13S1250, centromeric, to D13S267,
telomeric) spanning the BRCA2 gene locus were used for the haplotype analysis. Screening for the
8765delAG mutation was performed by PCR-based amplification of BRCA2-exon 20, followed by
automated sequencing.
Results: Among families with high recurrence of breast cancer (≥ 3 cases in first-degree relatives),
those from North Sardinia shared the same haplotype whereas the families from French Canadian
and Jewish-Yemenite populations presented distinct genetic assets at the BRCA2 locus. Screening
for the BRCA2-8765delAG variant among unselected and consecutively-collected breast cancer
patients originating from the entire Sardinia revealed that such a mutation is present in the
northern part of the island only [9/648 (1.4%) among cases from North Sardinia versus 0/493
among cases from South Sardinia].
Conclusion: The BRCA2-8765delAG has an independent origin in geographically and ethnically
distinct populations, acting as a founder mutation in North but not in South Sardinia. Since BRCA2-
8765delAG occurs within a triplet repeat sequence of AGAGAG, our study further confirmed the
existence of a mutational hot-spot at this genomic position (additional genetic factors within each
single population might be involved in generating such a mutation).
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Background
Breast Cancer (BC) is the most common malignancy
among women in industrialized countries. Germline
mutations in BRCA1 (MIM 113705) and BRCA2 (MIM
600185) genes account for cancer predisposition in
majority of families with BC recurrence. Positive family
history is indeed recognized as a high risk factor for devel-
oping the disease; about 10% of all breast cancers arise in
individuals carrying a germline mutation in one of such
two genes [1].
According to the Breast Cancer Information Core (BIC)
database [2], the majority of germline alterations identi-
fied in BRCA1  and  BRCA2  is unique (57% and 63%,
respectively); the remaining ones are recurrent founder
mutations which have been described in different ethnic
groups and populations [3]. Mutations that are observed
repeatedly associated with a common haplotype are likely
to have descended from a common ancestor, and are
referred to as "founder mutations". Although at different
rates, BRCA1  and BRCA2 founder mutation have been
detected in genetically homogeneous populations, such
as the Icelanders [4,5], the Ashkenazi Jews [6], the Finns
[7], and the French-Canadians [8].
The  BRCA2-8765delAG mutation was described as a
founder mutation in Jewish-Yemenite families [9], as well
as in French-Canadian families [8,10]. Our group has also
described the BRCA2-8765delAG variant as a founder
mutation in about 12% breast cancer families originating
from different villages of North Sardinia [11-13].
Although the age of the BRCA2-8765delAG variant has
not yet been determined, this mutation appears on an
ancient haplotype [11]. Moreover, the BRCA2-8765delAG
mutation has been demonstrated to be present in all
affected individuals from the four (57%) out of seven
breast cancer families who shared an identical-by-descent
haplotype within North Sardinia [11]. A previous study
has also reported the comparison of haplotypes of French
Canadians and Yemenite Jewish mutation carriers, indi-
cating the independent origins of carriers of the BRCA2-
8765delAG mutation in these two populations [14].
Overall, this mutation has been reported forty-two times
into the Breast Cancer Information Core database, and it
has been found to occur in populations throughout
Europe and North America. No information is however
available about the question whether BRCA2-8765delAG
may be an ancient or common mutation in Mediterra-
nean area (which Sardinia and Israel belong to). In this
sense, we performed a haplotype analysis among breast
cancer families carrying the BRCA2-8765delAG mutation
from Sardinian and Jewish-Yemenite populations (also
referring to data among French-Canadian families) as well
as definitely determined the prevalence of such a variant
among unselected breast cancer cases originating from the
entire Sardinia island.
Methods
Patients and families
Families containing probands with histologically-proven
diagnosis of breast cancer and carrying the BRCA2-
8765delAG mutation were recruited from clinics at the
University of Sassari and Azienda Unità Sanitaria Locale 1
of Sassari (which represent the principal medical institu-
tions accounting for cancer patients from the central and
northern parts of the island) and from familial cancer
genetics clinics in Israel; DNA samples of two French-
Canadian families carrying the BRCA2-8765delAG were
previously provided by P. Tonin. Sardinian families were
unrelated since they did not present any common ances-
tor after evaluation of pedigrees up to 1700.
All information regarding the recurrence of cancers in
family, age at cancer diagnosis, and age at death or current
age were collected after obtaining a written informed con-
sent. Most of the information were verified by analysis of
the Hospital records; all cancer diagnoses were confirmed
by pathology reports. After the patients were informed
about the aims and limits of the study, blood samples
were obtained with their written consent. DNA samples
were collected from at least one affected member of each
family.
Appropriate institutional informed consent guidelines
were followed for all recruited patients. The study was
reviewed and approved by the ethical review boards of
both participating institutions (University and Azienda
USL1 of Sassari).
DNA analysis
Haplotype analysis was performed using nine polymor-
phic microsatellite repeat markers, three intragenic
(D13S260, D13S1701, and D13S171) and the remaining
flanking the BRCA2  gene (D13S1250, D13S1299,
D13S1246, D13S289, D13S310 and D13S267). For these
markers, heterozygosity varied from 69% to 82%; primer
sequences and PCR conditions for amplification were as
indicated into the Human Genome Database [15]. Marker
loci were ordered as in Ensembl map [16] (Table 1). Alle-
les were numbered according to size for each microsatel-
lite marker.
Briefly, DNA samples from 32 individuals in 7 families
(three from North-Sardinia, two from Israel and two from
Canada) carrying the BRCA2-8765delAG mutation were
genotyped. All primers labelled with fluorescein deriva-
tives (5'-6-FAM, or 5'-HEX) were from MWG-Biotech
(Ebersberg, Germany). For each sample, 50 ng of genomic
DNA was amplified using 200 μmol/L deoxynucleotideBMC Cancer 2007, 7:132 http://www.biomedcentral.com/1471-2407/7/132
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triphosphates, 0.4 μmol/L primers, 1.5 mmol/L MgCl2,
and 0.625 units of Taq DNA Polymerase, according to
standard PCR procedures. Microsatellite genotyping was
carried out on an automated ABIPRISM 3100 DNA
sequencer (Applied Biosystems, Foster City, CA) and PCR
fragments were analysed using the Genescan 3.7.1® soft-
ware.
Genomic DNA for mutational screening of 1,141 unse-
lected breast cancer patients was isolated from both
peripheral blood samples (N = 691) and archival paraffin-
embedded tissues (N = 450), using standardized proce-
dures. To avoid any bias, paraffin-embedded normal tis-
sues from breast cancer patients were consecutively
collected; all cases were thus included regardless of age at
diagnosis, family history status, and disease features. Sar-
dinian origin was ascertained in all cases through genea-
logical studies. For mutation screening, exon 20 of the
BRCA2  gene was amplified and PCR products were
directly sequenced using an automated fluorescence-cycle
sequencer.
Results
For haplotype analysis, breast cancer families carrying the
BRCA2-8765delAG mutation and originating from
North-Sardinia (N = 3), Israel (N = 2), and French area of
Canada (N = 2) were included into the study. Among the
seven families, 32 members, including 16 probands with
histologically-proven diagnosis of breast cancer, were gen-
otyped with markers spanning the BRCA2 locus at chro-
mosome 13q12-q13. All families had at least three
individuals diagnosed with breast cancer in first-degree
relatives and presence of the BRCA2-8765delAG mutation
in all family probands from the three populations was
confirmed by direct sequencing (Figure 1). The BRCA2-
8765delAG mutation was absent in blood DNA from 103
unrelated healthy individuals (corresponding to 206
chromosomes), originating from the same geographical
area and used as normal controls. Pedigrees of analyzed
BC families from North Sardinia and Israel are shown in
Figure 2. For both French-Canadian families, one
proband along with the two parents from each family was
analyzed.
In Sardinian families, an identical haplotype was inferred
by genotyping all affected family members carrying the
BRCA2-8765delAG mutation with marker loci D13S1250
to D13S267 (centromeric to telomeric) (Table 1). This
unique haplotype (8-3-5-3-8-10-5-2) among BC families
from North Sardinia was not found in 80 control chromo-
somes from the same geographical area. Surprisingly, the
two Jewish-Yemenite families presented two different
haplotypes; one of them only, Fam.1, shared majority of
the alleles (5/9; 56%) observed into the Sardinian series
(Table 1). For the remaining French-Canadian families,
haplotype analysis was carried out for the three closely
flanking BRCA2 marker loci only (D13S260, D13S1701,
and D13S171), due to the low amount of the available
germline DNA. Although with such a limited number of
markers, the inferred haplotype of the French-Canadian
cases was consistent in families from the same population
but different when compared with familial cases from
both the Sardinian and Jewish-Yemenite populations
(Table 1). Overall, the BRCA2-8765delAG mutation was
found to occur associated with distinct haplotypes into
the three analyzed populations.
To evaluate the prevalence of BRCA2-8765delAG in breast
cancer cases across the entire Sardinia, we screened
genomic DNA obtained from both peripheral blood and
paraffin-embedded normal tissues (see Methods) of
1,141 unselected and consecutively-collected BC patients
originating from either the northern (N = 648) or south-
ern (N = 493) part of the island. The 2-bp deletion in exon
Table 1: Results from haplotype analysis
Cromo some Ensembl Map 
(Mb)
Marker North 
Sardinia
Jewish-Yemenite French-Canadian
Fam.1 Fam.2 Fam.1 Fam.2
13q12.3 27.80 D13S1250 8 8 5 n.t. n.t.
29.45 D13S1299 3 3 2 n.t. n.t.
30.00 D13S1246 5 4–8 1 n.t. n.t.
30.15 D13S289 3 3 3 n.t. n.t.
13q13.1 31.35 D13S260 8 8 3 7 7
31.80 BRCA2
32.05 D13S1701 6 5 5 8 8
32.15 D13S171 10 3–4 4 4–11 4–6
32.65 D13S310 5 5 3 n.t. n.t.
13q13.2 33.15 D13S267 2 5–8 8 n.t. n.t.
The genomic position of the BRCA2 gene is indicated. n.t., not testedBMC Cancer 2007, 7:132 http://www.biomedcentral.com/1471-2407/7/132
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20 of the BRCA2 gene was detected by direct automated
sequencing of the correspondent PCR products (Figure 1).
The  BRCA2-8765delAG mutation was found in 9/648
(1.4%) cases from North Sardinia and 0/493 cases from
South Sardinia (Figure 3). Interestingly, all the nine breast
cancer patients found positive to BRCA2-8765delAG were
from families with at least three affected members in first-
degree relatives [whereas familial recurrence of breast can-
cer was observed in 87 (13.5%) out of 644 mutation-neg-
ative patients, whose information on family history for
cancer was available], further confirming that occurrence
of the BRCA2 mutations is strictly associated with the
presence of a higher familial recurrence of the disease.
Discussion
The unique haplotype common to all three breast cancer
families from North Sardinia indicated the BRCA2-
8765delAG as a founder mutation in this geographical
area. Haplotype analysis revealed that Sardinian mutation
carriers shared majority of allele markers with only one of
the two Jewish-Yemenite families; the remaining Jewish-
Yemenite family and the French-Canadian families did
not present the same genotypic asset (see Table 1).
In the BIC database [2], the BRCA2-8765delAG variant is
a recurrent mutation occurring in a AG-rich sequence of
the BRCA2 gene. Recombination events or marker muta-
tions could theoretically account for haplotype divergence
from a single, original haplotype but seem not to be likely
explanations here. Indeed, our results indicate that carri-
ers of the BRCA2-8765delAG variant may have an inde-
pendent origin and, although already suggested for
French-Canadians and Yemenite-Jews [14], allow to
exclude the presence of a common ancestor in Mediterra-
nean area also. Therefore, one could hypothesize the exist-
ence of a mutational hot-spot at this genomic position
within the BRCA2 gene locus. Since the mutation is an
AG-deletion in a stretch of AGAGAG, the chance of recur-
BRCA2-8765delAG mutation Figure 1
BRCA2-8765delAG mutation. Electropherogram shows the nucleotide sequence at the genomic level in a positive breast 
cancer patient. The wild-type (WT) and the mutant (Mut) nucleotide sequences have been reported (the deleted AG has been 
boxed). Arrow indicates the mutation position.BMC Cancer 2007, 7:132 http://www.biomedcentral.com/1471-2407/7/132
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rent mutations at this site might be higher than that in a
site having a single AG. On this regard, differences into the
genetic background may be due to a replication slippage
resulting in the loss of repeat units during meiosis or
recombination events (putatively dependent on the
simultaneous presence of additional genetic factors or,
more in general, favouring genomic backgrounds). As a
confirmation of this hypothesis, other authors have
described different nucleotide deletions at this genomic
level among families with breast and/or ovarian cancer
[10,14,17,18]. Nevertheless, one should also take into
account that a deletion of AG in a triplet repeat sequence
of AGAGAG does not allow to accurately determine
whether the mutations that occur in the different popula-
tions are really identical.
Considering the incidence of the BRCA2-8765delAG vari-
ant among the unselected patients from the Sardinian
population, our extensive screening clearly indicated that
such a mutation is recurrent in North Sardinia (confirm-
ing its role as founder mutation in this part of the island
[11-13]) but absent in South Sardinia. The Sardinia island
has a relatively small, isolated, and genetically homogene-
ous population with a high rate of inbreeding; several
founder effects have been already demonstrated for
monogenic or complex diseases in this population [19].
For breast cancer, heterogeneous genetic backgrounds
seem to instead account for such deep differences into the
BRCA2 gene involvement. As we recently demonstrated
for malignant melanoma [20], these findings further sup-
port the hypothesis that patients' origin (even in so close
geographical areas) may determine different susceptibility
roles of the candidate cancer genes and, for the same gene,
different mutation rates might be observed.
As we previously described [11-13], the prevalence of the
BRCA2-8765delAG mutation in breast cancer families was
lower than that of other BRCA1-2  founder mutations
observed in different genetically-homogeneous popula-
tions (three BRCA1 and a single BRCA2 founder muta-
tions account for vast majority of breast cancer families
among Ashkenazi Jews [21] and Icelanders [22], respec-
tively). Considering the screening of consecutively-col-
lected unselected BC cases, the fraction of 1.4% BRCA2
mutation carriers is analogously low in breast cancer
patients from North Sardinia (again, a quite sharp con-
trast between our frequencies and those observed in unse-
lected cases from either Ashkenazi Jewish [23,24] and
Icelandic [22,25] populations was observed).
In conclusion, our study allowed to assess that BRCA2-
8765delAG, arising in conjunction with several and
Pedigrees of analyzed BRCA2-8765delAG positive families from Sardinian and Jewish-Yemenite populations Figure 2
Pedigrees of analyzed BRCA2-8765delAG positive families from Sardinian and Jewish-Yemenite populations. 
Arrows indicate the family members who underwent haplotype analysis. S and J-Y, Sardinian and Jewish-Yemenite families 
(respectively).BMC Cancer 2007, 7:132 http://www.biomedcentral.com/1471-2407/7/132
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clearly distinct genetic haplotypes, may be generated in an
independent manner and at a frequency higher than other
BRCA2 mutations among breast cancer families world-
wide. A clinically relevant implication is that such a recur-
rent mutation should be included in targeted BRCA2
mutation screening panels in any population, irrespective
of ethnic origin. Finally, our heterogeneous data from the
screening of breast cancer patients belonging to a so-rec-
ognized genetically-homogeneous population, can be fur-
ther considered as indicative that both role and mutation
prevalence of any candidate cancer gene needs to be eval-
uated in each geographical area.
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